reports
Preliminary results for the year ended 31 December 2024
Preliminary results for the year ended 31 December 2024 ~ Strong commercial momentum underpins transformative financial performance ~ Strong 2024 financial performance in line with guidance Revenue growth of 44% to £128.8 million compared to 2023, organic revenue growth of 81%1Operating EBITDA2 loss of £(15.3) million for the full year in line with expectations, Operating EBITDA profit of £5.0 million achieved in second half of 2024 Contracted value of client orders3 signed during 2024 reached approximately £186 million at 31 December 2024, an increase of c.35% compared to £138 million i...
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – ...
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & Gene Therapy – Global' category at the 2025 CDMO Leadership Awards. The annual CDMO Leadership Awards recognise excellence in contract development and manufacturing based on independent surveys from leading global biopharma ...
OXB to present at the Leerink Partners Global Healthcare Conference
OXB to present at the Leerink Partners Global Healthcare Conference OXB to present at the Leerink Partners Global Healthcare Conference Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Lucinda Crabtree, Chief Financial Officer, will take part in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday, 11 March 2025 at 2:20 PM EDT / 6:20 PM GMT. A live webcast of the fireside chat will be available on the ‘Investor Relations’ section of OXB’s website under ‘Resu...
OXB’s lentiviral vector manufacturing technology to support Boehringer...
OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis Commencement of LENTICLAIR™ 1 trial, utilising OXB lentiviral vectors; builds on long term collaboration with Boehringer Ingelheim Oxford, UK – 20 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces tha...
Appointment of Joint Corporate Broker and Joint Financial Adviser
Appointment of Joint Corporate Broker and Joint Financial Adviser Oxford, UK – 5 February 2025: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Jefferies International Limited ("Jefferies") as its Joint Corporate Broker and Joint Financial Adviser, to work alongside RBC Capital Markets, with immediate effect. -Ends- Enquiries: OXB: Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ICR Healthcare:T: +44 (0)20 3709 5700 / E: Mary-Jane Elliott / Angela Gray / Davide Salvi About OXB OXB (LS...
- Brian Moretta
- Mark Thomas
- Martin Hall
Hardman & Co Monthly: January 2025
Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ODX OMEGA DIAGNOSTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
ARBB ARBUTHNOT BANKING GROUP
APH ALLIANCE PHARMA PLC
FUM FUTURA MEDICAL PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
IMM IMMUPHARMA
PRM PROTEOME SCIENCES PLC
ACSO ACCESSO TECHNOLOGY GROUP
GNS GENUS PLC
SUN SURGICAL INNOVATIONS GROUP PLC
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
OMG OXFORD METRICS
EAH ECO ANIMAL HEALTH GROUP
JDG JUDGES SCIENTIFIC
VTAS VOLTA FINANCE (GBP)
SDI SDI GROUP
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
FARON FARON PHARMACEUTICALS OY
ONC ONCIMMUNE HOLDINGS
STX SHIELD THERAPEUTICS
CSN CHESNARA PLC
SNG SYNAIRGEN PLC
IPO IP GROUP
HAT H&T GROUP
SCLP SCANCELL HOLDINGS
SYNC SYNCONA
CIR CIRCASSIA GROUP
SPI SPIRE HEALTHCARE GROUP PLC
AGR ASSURA PLC
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
GDR GENEDRIVE
CTEC CONVATEC GROUP PLC
CREO CREO MEDICAL GROUP
SBTX SKINBIOTHERAPEUTICS
A0MXLB NB PRIVATE EQUITY PARTNERS
FAB FUSION ANTIBODIES
IXI IXICO
OXB OXFORD BIOMEDICA PLC
ABDX ABINGDON HEALTH
IMCR IMMUNOCORE HOLDINGS ADS
POLX POLAREAN IMAGING
AREC ARECOR THERAPEUTICS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
SAR SAREUM HOLDINGS PLC
BAI BENEVOLENTAI
4BB 4BASEBIO PLC
TISSUE REGENIX GROUP PLC
- Martin Hall
Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector. The HHI fell 17.7% to 398.9, underperforming all its benchmarks – FTSE 100 (+5.7%), FTSE All-Share (5.6%) and the FTSE AIM All-Share Index (-5...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ODX OMEGA DIAGNOSTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
APH ALLIANCE PHARMA PLC
FUM FUTURA MEDICAL PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
IMM IMMUPHARMA
PRM PROTEOME SCIENCES PLC
GNS GENUS PLC
SUN SURGICAL INNOVATIONS GROUP PLC
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
OMG OXFORD METRICS
EAH ECO ANIMAL HEALTH GROUP
JDG JUDGES SCIENTIFIC
SDI SDI GROUP
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
FARON FARON PHARMACEUTICALS OY
ONC ONCIMMUNE HOLDINGS
STX SHIELD THERAPEUTICS
SNG SYNAIRGEN PLC
IPO IP GROUP
SCLP SCANCELL HOLDINGS
SYNC SYNCONA
CIR CIRCASSIA GROUP
SPI SPIRE HEALTHCARE GROUP PLC
AGR ASSURA PLC
GDR GENEDRIVE
CTEC CONVATEC GROUP PLC
CREO CREO MEDICAL GROUP
SBTX SKINBIOTHERAPEUTICS
FAB FUSION ANTIBODIES
IXI IXICO
OXB OXFORD BIOMEDICA PLC
TXG 10X GENOMICS INC CLASS A
ABDX ABINGDON HEALTH
IMCR IMMUNOCORE HOLDINGS ADS
POLX POLAREAN IMAGING
AREC ARECOR THERAPEUTICS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
SAR SAREUM HOLDINGS PLC
BAI BENEVOLENTAI
4BB 4BASEBIO PLC
Z29 TISSUE REGENIX GROUP PLC
029 GROUP SE
OXB to host a free webinar on accelerating development of viral vector...
OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development Oxford, UK – 20 November 2024: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces it will host a free 60-minute webinar exploring how advanced robotics can be used to speed up the development of viral vector drug products. The webinar titled "Accelerating Viral Vector Manufacturing: The Use of ...
Interim Results for the Six Months Ended 30 June 2024
Interim Results for the Six Months Ended 30 June 2024 Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued execution of "One OXB" strategy with global integration progressing across UK, US and French operationsExisting near-term and medium-term financial guidance reiterated, supported by positive growth trajectory of the business Continued strong demand for OXB's CDMO services, with an increase in number of late stage programmes Client portfolio is maturing and now includes 37 clients and 48 programme...
Oxford Biomedica rebrands as OXB reinforcing transformation into leadi...
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 September 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the launch of its new corporate brand. Oxford Biomedica is rebranding as OXB, unveiling a more modern and recognisable visual identity that reinforces its transformation into a global pure-play cell and gene therapy CDMO. The new identity reflects OXB’s unique ...
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer tod...
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a quality and innovation-led cell and gene therapy CDMO, announces that Lucinda (Lucy) Crabtree Ph.D. has today joined Oxford Biomedica as Chief Financial Officer (CFO) and board member. Lucinda’s appointment was previously on 17 July 2024. Lucinda Crabtree was previously at MorphoSys AG where she served as CFO, leading a finance team acr...
Oxford Biomedica to host a free webinar showcasing its AAV expertise
Oxford Biomedica to host a free webinar showcasing its AAV expertise Oxford Biomedica to host a free webinar showcasing its AAV expertise Oxford, UK - 27 August 2024: On Wednesday 11 September 2024, Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, will host a free 60-minute webinar on its adeno-associated virus (AAV) development expertise and showcase their recent breakthroughs. The webinar titled “Advanced AAV Processing and Potency through Characterisation of Capsid and Payload Heterogeneity” will feature presentations by: Sarah Laughlin-Toth, PhD, Senior Scie...
Oxford Biomedica – Half Year Trading Update and Notice of Interim Resu...
Oxford Biomedica – Half Year Trading Update and Notice of Interim Results Half Year Trading Update and Notice of Interim Results Full year 2024 revenue and medium-term financial guidance reiterated; underpinned by OXB’s growing market share in the expanding cell and gene therapy marketContracted value of client orders in the first seven months of the year reflective of strong demand for CDMO services at approximately £80 million Revenue backlog stood at approximately £113 million at 31 July 2024; high level of GMP suite reservation for 2025 gives increased visibility and underpins confiden...
Oxford Biomedica announces CFO transition
Oxford Biomedica announces CFO transition Oxford Biomedica announces Chief Financial Officer transition - Lucinda Crabtree to join as Chief Financial Officer - Oxford, UK – 17 July 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Lucinda (Lucy) Crabtree Ph.D. as Chief Financial Officer (CFO) and Board member. Simultaneously, the Company announces that Stuart Paynter will step down as CFO and from the Board after almost seven years of service. These changes will bec...
Update to Medium-Term Financial Guidance and 2023 Trading and Notice o...
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%Projected FY2024 revenue range of £126 million to £134 million, reflecting the successful integration of ABL Europe and anticipated growth from new and existing client programmesFY2023 revenues and EBITDA expected to be in line with guidance provided at the Interim ResultsFY2023 Preliminary Results to be reported on Mon...
Oxford Biomedica completes acquisition of ABL Europe
Oxford Biomedica completes acquisition of ABL Europe Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UKExpands Oxford Biomedica’s ability to serve more clients, unlocking development capacity and increasing revenues3.2 per cent of the Company’s share capital issued to Institut Mérieux at a share price of 407.4p Oxford, UK – 29 January 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and...
Oxford Biomedica is hosting a free webinar to share clients’ success s...
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, will host a free 60-minute webinar offering an in-depth view of the customer journey from client onboarding to the successful manufacture of adeno-associated virus and lentiviral vectors.. This event will demonstrate how unique and transferable techni...
- Martin Hall
Hardman & Co Healthcare Index: 2023 – Capital demands dent performance
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ETX E-THERAPEUTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
APH ALLIANCE PHARMA PLC
AVO ADVANCED ONCOTHERAPY
OXB OXFORD BIOMEDICA PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
SN/ IMMUPHARMA
IMM PROTEOME SCIENCES PLC
PRM GENUS PLC
GNS SURGICAL INNOVATIONS GROUP PLC
SUN ADVANCED MEDICAL SOLUTIONS GROUP PLC
AMS OXFORD METRICS
OMG ECO ANIMAL HEALTH GROUP
EAH SDI GROUP
SDI HVIVO
HVO INDIVIOR PLC
INDV VALIRX
VAL SHIELD THERAPEUTICS
STX SYNAIRGEN PLC
SNG IP GROUP
IPO SCANCELL HOLDINGS
SCLP SYNCONA
SYNC ERGOMED
ERGO SPIRE HEALTHCARE GROUP PLC
SPI REDX PHARMA
REDX ASSURA PLC
AGR GENEDRIVE
GDR SPIRE INC
SR CONVATEC GROUP PLC
CTEC DESTINY PHARMA
DEST RENEURON GROUP
RENE IXICO
IXI 10X GENOMICS INC CLASS A
TXG INDIVA LTD
NDVA IMMUNOCORE HOLDINGS ADS
IMCR 2SEVENTY BIO INC
TSVT OXFORD NANOPORE TECHNOLOGIES PLC
ONT SILENCE THERAPEUTICS PLC
SLN SAREUM HOLDINGS PLC
SAR BENEVOLENTAI
BAI 123FAHRSCHULE SE
123F 1895 BANCORP OF WISCONSIN INC
BCOW TISSUE REGENIX GROUP PLC
PLP.H 3D SIGNATURES INC
Z29 029 GROUP SE
Business Update
Business Update Business Update Current contracted value signed in 2023 of £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing)On track to achieve 2023 guidance provided at the Interim Results and reiteration of medium term guidance; growth supported by new orders recently signed across lentivirus, adeno-associated virus (AAV) and adenoviral vectorsProgress towards multi-vector multi-site model with transfer of lentiviral vector capabilities to Bedford, Massachusetts site and acquisition of ABL EuropeRecru...
Oxford Biomedica signs agreement to acquire ABL Europe from Institut M...
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO Oxford Biomedica announces the signing of a sale and purchase agreement with Institut Mérieux for the acquisition of ABL Europe The transaction Provides Oxford Biomedica with multi viral vector CDMO capabilities – to be made available across the Company’s six manufacturing sites in EU, US and UKExpands Oxford Biomedica’s capacity in proce...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.